Achieve Life Sciences (ACHV) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1-year price objectives for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they predict the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 201.1% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.

Achieve Life Sciences' stock was trading at $2.45 at the beginning of the year. Since then, ACHV shares have increased by 153.1% and is now trading at $6.20.
View the best growth stocks for 2023 here.

Achieve Life Sciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 633,200 shares, an increase of 11.2% from the April 30th total of 569,600 shares. Based on an average daily volume of 156,300 shares, the short-interest ratio is currently 4.1 days.
View Achieve Life Sciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our ACHV earnings forecast.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, March, 16th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. During the same period in the prior year, the firm posted ($0.76) earnings per share.

Shares of Achieve Life Sciences reverse split before market open on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Achieve Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.00%), LPL Financial LLC (0.80%), Long Focus Capital Management LLC (0.78%), Perkins Capital Management Inc. (0.77%), Raymond James & Associates (0.58%) and Susquehanna International Group LLP (0.00%).
View institutional ownership trends.

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACHV stock can currently be purchased for approximately $6.20.

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $111.85 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.76) on an earnings per share basis.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.